使用高达9.3 GBq治疗活度的重复177Lu标记PSMA-617放射配体治疗
该回顾性研究纳入40例晚期前列腺癌且PSMA显像阳性患者,分4组分别接受4、6、7.4、9.3 GBq的177Lu-PSMA-617治疗,每2个月一次共3周期。初始PSA反应与治疗活度无相关性;完成3周期后8周,4组分别有2/10、4/10、4/10、7/10例达部分缓解,但因患者数少不能证明正相关剂量-反应关系。急性血液学毒性也与活度无关,每组不超过1例出现3/4级毒性,但9.3 GBq组平均血小板计数随时间慢性下降。
要点
- 4组初始PSA反应与治疗活度无相关性。
- 完成3周期后8周部分缓解:4 GBq组2/10、6 GBq组4/10、7.4 GBq组4/10、9.3 GBq组7/10。
- 急性血液学毒性与活度无关,每组3/4级毒性不超过1例;9.3 GBq组平均血小板计数随时间慢性下降。
核心结论
- 若排除弥漫性红骨髓浸润和广泛化疗预处理的患者,每2个月最多3次注射9.3 GBq的177Lu-PSMA-617耐受良好。
- 进一步剂量递增应谨慎进行,因为最高剂量似乎接近最大耐受剂量。
研究设计与样本
- 回顾性报告40例晚期前列腺癌且PSMA显像阳性摄取患者的临床观察,每2个月治疗一次。
- 分4组每组10例,分别接受4 GBq/80 nmol前体、6 GBq/120 nmol前体、7.4 GBq/150 nmol前体或9.3 GBq/150 nmol前体的177Lu活度。
- 每2周实验室检查安全性,每4周检查PSA反应,其他效应通过病史评估。
主要发现
- 初始PSA反应与治疗活度无相关性。
- 完成全部3周期后8周部分缓解:4 GBq组2/10、6 GBq组4/10、7.4 GBq组4/10、9.3 GBq组7/10。
- 该发现与正性剂量-反应关系相符,但因患者数少不能证明该关系。
- 急性血液学毒性与治疗活度无相关性,每组3/4级毒性不超过1例。
- 与其他组不同,9.3 GBq组平均血小板计数随时间慢性下降。
临床怎么用
- 若排除弥漫性红骨髓浸润和广泛化疗预处理的患者,每2个月最多3次注射9.3 GBq的177Lu-PSMA-617耐受良好。
- 进一步剂量递增应谨慎进行,因为最高剂量似乎接近最大耐受剂量。
局限性
- 因患者数少,该发现不能证明正性剂量-反应关系。
- 进一步剂量递增应谨慎进行,因为最高剂量似乎接近最大耐受剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current treatment protocols for 177Lu-labeled PSMA-617 therapies were cautiously derived from dosimetry data, but their practical appropriateness has not yet been proven clinically. We retrospectively report our clinical observations using 4 different treatment activities. Methods: Forty patients with advanced prostate cancer and positive uptake in prostate-specific membrane antigen (PSMA) imaging were treated with 4 GBq of 177Lu activity/80 nmol of precursor, 6 GBq of 177Lu activity/120 nmol of precursor, 7.4 GBq of 177Lu activity/150 nmol of precursor, or 9.3 GBq of 177Lu activity/150 nmol of precursor (10 patients per group) every 2 mo. Safety was checked every 2 wk by laboratory tests, the prostate-specific antigen response was checked every 4 wk, and other effects were assessed by anamnesis. Results: The initial prostate-specific antigen response showed no correlation with treatment activity. However, 2 of 10, 4 of 10, 4 of 10, and 7 of 10 patients receiving doses of 4, 6, 7.4, and 9.3 GBq, respectively, were in partial remission 8 wk after completing all 3 cycles. This finding would be in line with but-because of low patient numbers-would not prove a positive dose-response relationship. Acute hematologic toxicity was also not correlated with treatment activity, and no more than 1 patient per group had grade 3/4 toxicity. Nevertheless, in contrast to the findings for the other groups, the mean platelet count in the 9.3-GBq group decreased chronically over time. Conclusion: If patients with diffuse red marrow infiltration and extensive chemotherapeutic pretreatments are excluded, then treatment activities of up to 3 injections of 9.3 GBq of 177Lu-PSMA-617 every 2 mo are tolerated well. Further dose escalation should be conducted with care, as the highest dose seems to be close to the maximum tolerable dose.
引用
- Rathke H, Giesel FL, Flechsig P, et al. Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq. J Nucl Med. 2017. PMID: 28798031. doi:10.2967/jnumed.117.194209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。